France· FR:63052124
MAVIRET 100 mg/40 mg, comprimé pelliculé
A medicinal product containing glécaprévir + pibrentasvir, registered in France by ABBVIE DEUTSCHLAND (ALLEMAGNE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- GLÉCAPRÉVIR + PIBRENTASVIR
- Manufacturer
- ABBVIE DEUTSCHLAND (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009301087654 plaquette(s) PVC polyéthylène polychlortrifluoroéthylène aluminium de 21 comprimé(s)EUR 11.16
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Glécaprévir + pibrentasvir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesMavyretAbbVie Inc.
- United KingdomGlecaprevir 100mg / Pibrentasvir 40mg tabletsAbbVie Ltd
- SpainMAVIRET 100 MG/40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAbbvie Deutschland Gmbh & Co. Kg
- FinlandMaviretAbbVie Deutschland GmbH&Co.KG
- IrelandMaviret 100 mg/40 mg film-coated tabletsAbbVie Deutschland GmbH & Co. KG
- CzechiaMAVIRETAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- PolandMaviretAbbVie Deutschland GmbH & Co. KG
- SwedenMaviret 100 mg/40 mg Filmdragerad tablettAbbVie Deutschland GmbH & Co KG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Glecaprevir/Pibrentasvir Abbvie
- Iceland · Maviret
- Liechtenstein · Maviret
- Norway · Maviret
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf586580-b56e-4c17-ba2b-141676d7e000 GET /v1/drugs/bf586580-b56e-4c17-ba2b-141676d7e000?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63052124",
"date_amm": "2017-07-26",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/17/1213",
"substance": "GLÉCAPRÉVIR + PIBRENTASVIR",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about glécaprévir + pibrentasvir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.